发现诃子酸和石榴皮苷为新型严重急性呼吸综合征冠状病毒2 3CL的变构抑制剂。

Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL.

作者信息

Du Ruikun, Cooper Laura, Chen Zinuo, Lee Hyun, Rong Lijun, Cui Qinghua

机构信息

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China; Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China; Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao, 266122, China.

Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA.

出版信息

Antiviral Res. 2021 Jun;190:105075. doi: 10.1016/j.antiviral.2021.105075. Epub 2021 Apr 17.

The emerging SARS-CoV-2 infection is the cause of the global COVID-19 pandemic. To date, there are limited therapeutic options available to fight this disease. Here we examined the inhibitory abilities of two broad-spectrum antiviral natural products chebulagic acid (CHLA) and punicalagin (PUG) against SARS-CoV-2 viral replication. Both CHLA and PUG reduced virus-induced plaque formation in Vero-E6 monolayer at noncytotoxic concentrations, by targeting the enzymatic activity of viral 3-chymotrypsin-like cysteine protease (3CL) as allosteric regulators. Our study demonstrates the potential use of CHLA and PUG as novel COVID-19 therapies.